Inside Martin Varsavsky's Health-tech and Bio-tech Portfolio
Exploring Martin Varsavsky's Strategic Investments.
Subscribe: If this newsletter was forwarded to you, subscribe here.
Martin is a fellow Argentinean entrepreneur based in Madrid. With a long trajectory in the telecommunications sector, he has founded companies like Viatel, Jazztel (IPO 1999), Ya.com (acquired by T-Online), and Fon.
Martin faced a setback in his life when he and his wife tried to start a family. Shortly after their marriage, 31-year-old Nina discovered she was dealing with infertility challenges. For this reason, in 2015 Martin founded Prelude Fertility/Inception now the largest chain of fertility clinics in the USA. Two years later he also founded Overture Life, focused on automating the embryology lab.
Let’s take a look at the key points that are the pillars of his investment strategy:
Investment Strategy Key Points:
Fertility, Longevity, and Healthspan: Invests in companies that extend human lifespan and improve quality of life.
Early-stage Investments: Often invests in early-stage startups with high growth potential via Martin Varsavsky's early-stage investment fund, VAS Ventures.
Cross-disciplinary Approaches: Prefers companies that combine biology, technology, and data science.
Global Reach: Investments are not restricted by geography, though there is a significant presence in North America and Europe.
Companies Invested In
1. Gameto
Total Funding: $73 million
Industry: Fertility
Description: Gameto is a biotech company focused on using cell engineering to develop therapeutics for diseases of the female reproductive system. They aim to address issues related to menopause and reproductive longevity.
I like how Gameto is innovating in cell engineering to address menopause and reproductive longevity, targeting significant unmet needs.
2. Prelude Fertility
Total Funding: $200 million
Industry: Fertility
Description: The Prelude Network is the fastest-growing network of fertility clinics and the largest provider of comprehensive fertility services in the U.S.
Despite being the largest provider in a growing market with stable revenue potential, Prelude Fertility faces high operational costs and increasing competition.
3. Overture Life
Total Funding: $52.4 million
Industry: Fertility
Description: Overture Life is a clinical-stage biotechnology company focused on automating assisted reproductive processes to enhance IVF outcomes. Its innovative technologies standardize fertility treatments, simplifying techniques and optimizing resources to make reproductive care more affordable, reliable, and accessible.
Automation and non-invasive techniques could revolutionize IVF outcomes, reduce costs, and increase success rates.
4. Aura Bioscience
Total Funding: $381 million (NASDAQ:AURA)
Industry: Oncology
Description: Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications.
Aura Biosciences' innovative VDC technology targets multiple oncology indications, offering strong potential for disruptive cancer treatments.
5. Motiv
Total Funding: $25.7 million
Industry: Preventive Health
Description: Motiv is a wearable technology company focused on designing products that fit seamlessly into people's lives and keep them living better. Motiv’s first product, Motiv Ring, is sold internationally, in Europe, Asia, the Middle East, Australia and New Zealand.
Motiv is an interesting business, but it faces high risks such as intense competition and dependency on consumer adoption.
6. Jawbone Health
Total Funding: $65.5 million
Industry: Primary Care
Description: Jawbone Health is at the forefront of revolutionizing primary care for millions of patients worldwide.
7. Braid Health
Total Funding: $12 million
Industry: Healthcare Diagnostics
Description: Braid Health is redefining the landscape of healthcare diagnostics with its innovative approach to real-time radiology and medical imaging. The company provides healthcare professionals with the tools they need to deliver immediate, high-resolution diagnostic results.
Braid Health offers the right product at the right time, addressing the growing demand for advanced diagnostics.
8. 23andME
Total Funding: $1.1 billion (NASDAQ:ME)
Industry: Genetics
Description: 23andMe, is a leading consumer genetics and research company. 23andMe has created the world’s largest crowdsourced platform for genetic research.
Despite the data breach lawsuit, for which 23andMe reached a settlement this week, it remains a leading consumer genetics and research platform with a strong brand and significant market presence.
9. Forward
Total Funding: $325 million
Industry: Preventive Health
Description: Forward is a startup redesigning the way we deliver healthcare using all the technologies healthcare has neglected: sensors, mobile, and AI. The company is funded by some of the world's best investors and entrepreneurs including First Round Capital, Eric Schmidt (Google/Alphabet chairman), Marc Benioff (Salesforce founder), Joe Lonsdale (Palantir founder), Joshua Kushner (Oscar co-founder) and Garrett Camp (Uber co-founder).
Forward is on the right track by emphasizing preventive health with innovative technologies.
10. Daye
Total Funding: $17.1 million
Industry: Fem-tech
Description: Daye is a gynecological health company that creates products and services for vaginal treatment. The company started with the invention of the world’s first pain-relieving tampon, designed to support the 90% of women who experience menstrual cramps.
Daye offers a unique product addressing menstrual cramps, with significant market potential and opportunities for product diversification.
Portfolio Analysis
Martin’s portfolio includes a mix of early-stage startups and established companies, all pushing the boundaries of science and technology in healthcare. This diversification aims to balance risk and potential returns by investing in both established and emerging companies with innovative technologies.
Overall Strengths:
Innovation Potential: These companies are at the forefront of technological advancements, offering high growth potential.
Market Demand: Addressing critical and growing healthcare needs, such as fertility, oncology, and preventive health.
Overall Risks:
High R&D and Operational Costs: Many companies require substantial investment with uncertain returns, especially those in the early stages.
Regulatory Challenges: Strict regulatory environments can delay or impede progress across various sectors.
Market Competition: Intense competition necessitates continuous innovation and market adaptation.
+ Health-tech is good
Other topics you might find interesting 💡📍 VCs Pour Over $220 Million into This Business Model
👉 Click here to read the full article.
📍7 Companies Pioneering Health-Tech AI in Spain
👉 Click here to read the full article.
Suggestion? Critiques? Send your feedback in this link or reply to this e-mail.
This newsletter can impact those around you. Feel free to share it.
